Neumora Therapeutics, Inc.
No enriched coverage for $NMRA in the last 7 days.
No SEC Form 4 filings for $NMRA in the last 30 days.
See all $NMRA insider activity →Aurora Daljit Singh (See Remarks) sold 87,766 indirectly-held shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.53 ($1.51–$1.60, $0.13M total) across 2 trades over 2026-08-20 to 2026-08-21.
Aurora Daljit Singh (See Remarks) sold 88,294 shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.53 ($1.51–$1.59, $0.14M total) across 2 trades over 2026-08-20 to 2026-08-21.
Aurora Daljit Singh (See Remarks) sold 120,921 indirectly-held shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.56 ($1.50–$1.65, $0.19M total) across 3 trades over 2026-08-17 to 2026-08-19.
Recent NMRA coverage spans insider activity, financial news and earnings.
Insider sale may signal lack of confidence, but size is modest for a microcap.
The insider sale may signal reduced confidence or liquidity needs, potentially pressuring the stock short-term.
Minor dilution of insider ownership; unlikely to move price materially.
The insider sale may signal reduced confidence, potentially pressuring the stock short-term.
Clinical and runway updates shift near-term catalyst expectations and funding-duration risk for NMRA.
AlphAI scores every news story that mentions NMRA with an AI model for sentiment and relevance, and aggregates insider trades from Neumora Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aurora Daljit Singh (See Remarks) sold 87,766 indirectly-held shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.53 ($1.51–$1.60, $0.13M total) across 2 trades over 2026-08-20 to 2026-08-21.
1 min readAurora Daljit Singh (See Remarks) sold 88,294 shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.53 ($1.51–$1.59, $0.14M total) across 2 trades over 2026-08-20 to 2026-08-21.
1 min readAurora Daljit Singh (See Remarks) sold 120,921 indirectly-held shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.56 ($1.50–$1.65, $0.19M total) across 3 trades over 2026-08-17 to 2026-08-19.
1 min readAurora Daljit Singh (See Remarks) sold 156,852 shares of Neumora Therapeutics, Inc. (NMRA) at an average of $1.55 ($1.49–$1.65, $0.24M total) across 4 trades over 2026-08-17 to 2026-08-19.
1 min readNeumora Therapeutics (Nasdaq: NMRA) reported Q2 2026 results and a pipeline update. It said NMRA-215 IND submission is planned for Q4 2026 with Phase 1 initiation by year end. NMRA-511 AD agitation data are expected in Q4 2026, and NMRA-898 schizophrenia Phase 1 data in 2H 2026. Cash was $116.8M, funding operations into Q3 2027; Q2 net loss was $43.1M.
4 min readNeumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzhe
6 min readBiotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.
6 min readNeumora Therapeutics, Inc. (NMRA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001885522 0001885522 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
6 min readThe article indicates that Neumora exceeded fourth-quarter earnings forecasts, driven by progress in its pipeline. Despite the positive financial performance and pipeline advancements, the company's shares experienced a decline.
3 min readNeumora Therapeutics has been downgraded from 'Strong Buy' to 'Hold' following the failure of its KOASTAL-1 study for navacaprant in Major Depressive Disorder (MDD). Although enrollment for KOASTAL-2 and KOASTAL-3 studies in MDD has increased with topline data expected in Q2 2026, success is uncertain. The company's NMRA-511 showed a promising signal for Alzheimer's Disease agitation in a Phase 1b study, particularly in patients with elevated anxiety, but a Phase 2 study is not anticipated until Q1 2027, delaying near-term value realization.
4 min read
